JPRN-UMIN000013607已完成未知
Observational study of Pertuzumab,Trastuzumab and taxane combination therapy for patient with pretreated HER2-positive advanced or recurrent breast cancer. - Observational study of Pertuzumab combination therapy for pretreated HER2-positive MBC.
Shonankamakura General Hospital0 个研究点目标入组 50 人开始时间: 2014年4月2日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patient with history of severe allergy. 2) Patient with history of Pertuzumab treatment. 3) Patient with other malignancy under treatment. 4) Patient with active infectious disease. 5) Patient with severe complications, 6) Patient with history of interstitial neumonitis to pulmonary fibrosis. 7) Patient with uncontrollable pleural effusion or ascites. 8) Patient with symptomatic brain metastasis. 9) Pregnant women, nursing mothers, women with possibility of pregnancy or women with no intention to contraception. 10) Patient with psychiatric disease who were considered to be inappropriate. 11)Other patients who were considered by the primary care physician to be inappropriate as subjects of this trial.
研究者
相似试验
进行中（未招募）
2 期
Extension study for HER2 amplified advanced solid tumors (JUPITER ES)JPRN-jRCTs031220444Ikeda Sadakatsu3
已完成
不适用
Early monitoring of trastuzumab +/- pertuzumab therapy with 18F-choline PET/CT in patients with advanced disease breastcancer.NL-OMON39351Catharina-ziekenhuis23
已完成
2 期
A phase II trial of pertuzumab and trastuzumab in combination with capecitabine in patients with metastatic breast cancer who received prior trastuzumab combination chemotherapy.Breast cancerJPRN-UMIN000012208Kurume University Hospital24
招募中
不适用
Observational study of Pertuzumab in combination with Trastuzumab and Docetaxel in patients with metastatic HER2-positive breast cancer that have the history of Trastuzumab treatmentmetastatic breast cancerJPRN-UMIN000012444Osaka City University Graduate School of Medicine20
招募中
2 期
A Phase II study of pertuzumab+trastuzumab+capecitabine in Patients with taxans and trastuzumab refractory for advanced or recurrent breast cancerHER2-positive metastatic breast cancerJPRN-UMIN000012030Saitama Breast Cancer Clinical Study Group30